United States · Venture startup

Who invested in Navrogen

One round we have observed, with the 3 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Biotech

Funding summaryUpdated 26 Oct 2026

Undisclosedraised across 1 round since 2025, from 1 source

Latest round: VentureSept 2025
Investors: 3

See who backed them

The rounds

Sept 2025
VentureAmount undisclosed
Source recorded

Founders and team

From Navrogen's own website and the SEC filings it signed: 5 on the team.

Nick NicolaidesChief Executive Officer
Nicholas C. NicolaidesCEO and Director will use the proceeds to expand operations and the research and development pipeline.i
Luigi C. GrassoChief Scientific Officer
Steven KyriakosVP of Finance
Brad KlineSenior Director of Research and Development

On the board, as filediLeon O Moulder

Everyone who backed them

Ben Franklin Technology PartnersGovernment1round

Ben Franklin Technology Partners of Southeastern PennsylvaniaGovernment1round

National Cancer Institute (NCI)Investment firm1round

Missing a round, or an investor who was in one? Tell us.

Quick answers about Navrogen

Who invested in Navrogen?

Navrogen's investors include Ben Franklin Technology Partners, Ben Franklin Technology Partners of Southeastern Pennsylvania and National Cancer Institute (NCI).

How much has Navrogen raised?

Navrogen has raised 1 round since 2025, none with a disclosed amount.

When did Navrogen last raise?

Navrogen's most recent round was a Venture in Sept 2025.

Who backed Navrogen first?

Navrogen's first round on record, in Sept 2025, was backed by Ben Franklin Technology Partners, Ben Franklin Technology Partners of Southeastern Pennsylvania and National Cancer Institute (NCI).